Gp100:209-217(210M)

Gp100:209-217(210M) is a peptide that is used in the field of oncology to stimulate the body's immune response against melanoma, a type of skin cancer. It is a modified version of a naturally occurring peptide, and is used in conjunction with other treatments to enhance their effectiveness.

Overview

Gp100:209-217(210M) is a peptide that is derived from the gp100 protein, which is expressed in melanoma cells. The peptide is modified at position 210 to enhance its ability to bind to HLA-A2, a molecule that is found on the surface of many human cells. This binding stimulates the immune system to recognize and attack melanoma cells.

Mechanism of Action

The mechanism of action of Gp100:209-217(210M) involves the stimulation of the body's immune response. The peptide binds to HLA-A2 molecules on the surface of cells, presenting it to T cells, a type of white blood cell. This triggers an immune response, with the T cells recognizing the peptide as foreign and attacking cells that express it. This includes melanoma cells, which express the gp100 protein from which the peptide is derived.

Clinical Use

Gp100:209-217(210M) is used in the treatment of melanoma, often in conjunction with other treatments such as chemotherapy or radiation therapy. It is administered as a vaccine, with the aim of stimulating the body's immune system to attack the cancer cells. Clinical trials have shown that it can enhance the effectiveness of these other treatments, leading to improved outcomes for patients.

Side Effects

As with any treatment, Gp100:209-217(210M) can have side effects. These can include fever, fatigue, and nausea. In some cases, the immune response it stimulates can also lead to autoimmune reactions, where the body's immune system attacks its own cells.

See Also

• Melanoma
• Immunotherapy
• Peptide vaccine